OVID Ovid Therapeutics Forecast, Technical & Fundamental Analysis
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders... Show more
OVID is expected to report earnings to fall 4.17% to -11 cents per share on August 18
Q2'26
Est.
$-0.12
Q1'26
Est.
$-0.12
Q4'25
Beat
by $0.17
Q3'25
Missed
by $0.02
Q2'25
Beat
by $0.10
The last earnings report on May 12 showed earnings per share of -11 cents, meeting the estimate of -11 cents. With 1.00M shares outstanding, the current market capitalization sits at 414.34M.
A.I. Advisor
published General Information
General Information
Provides medicines to children and adults with neurological disorders
A.I.dvisor indicates that over the last year, OVID has been loosely correlated with STOK. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if OVID jumps, then STOK could also see price increases.
OVID in upward trend: price may ascend as a result of having broken its lower Bollinger Band on July 31, 2026
OVID may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 41 cases where OVID's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where OVID advanced for three days, in of 270 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OVID as a result. In of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for OVID turned negative on July 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 57 similar instances when the indicator turned negative. In of the 57 cases the stock turned lower in the days that followed. This puts the odds of success at .
OVID moved below its 50-day moving average on July 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for OVID crossed bearishly below the 50-day moving average on July 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OVID declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.090) is normal, around the industry mean (19.620). P/E Ratio (0.000) is within average values for comparable stocks, (38.277). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.532). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (28.090) is also within normal values, averaging (420.906).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. OVID’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OVID’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
